Therapy for Mild to Moderate Asthma
Authors:
Open Access
- 9 August 2022
- journal article
- editorial
- Published by American Medical Association (AMA) in JAMA
- Vol. 328 (6) , 575-576
Abstract
Asthma is a disease characterized by recurring, reversible airways obstruction due to underlying inflammation and bronchial hyperresponsiveness. Asthma is one of the most common chronic noncommunicable diseases, affects an estimated 260 million people globally, and is associated with significant morbidity and mortality.1 Asthma with usually mild or infrequent symptoms (50%-75% of patients with asthma) contributes to 30% to 40% of exacerbations leading to emergency care; asthma-related death may occur in persons with asthma that is usually mild.2Keywords
This publication has 8 references indexed in Scilit:
- Asthma patients' and physicians’ perspectives on the burden and management of asthmaRespiratory Medicine, 2021
- Controlled Trial of Budesonide–Formoterol as Needed for Mild AsthmaNew England Journal of Medicine, 2019
- Improving the Affordability of Prescription Medications for People with Chronic Respiratory Disease: An Official American Thoracic Society Policy StatementAmerican Journal of Respiratory and Critical Care Medicine, 2018
- As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild AsthmaNew England Journal of Medicine, 2018
- Inhaled Combined Budesonide–Formoterol as Needed in Mild AsthmaNew England Journal of Medicine, 2018
- Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent AsthmaJAMA, 2018
- Short-acting β-agonist use and its ability to predict future asthma-related outcomesAnnals of Allergy, Asthma & Immunology, 2012
- Low-Dose Inhaled Corticosteroids and the Prevention of Death from AsthmaNew England Journal of Medicine, 2000